Mangelnde Transparenz bei Schutzfristen
Definition
Absence of public database for protection periods hinders planning for biosimilars and licensing, causing decision errors in commercialization strategy.
Key Findings
- Financial Impact: 1-2 years delayed market entry, 10-20% revenue loss per product
- Frequency: Per licensed technology
- Root Cause: No centralized EUIPO database for biotech exclusivities
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Biotechnology Research.
Affected Stakeholders
IP Managers, Business Development, CEOs
Deep Analysis (Premium)
Financial Impact
Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.
Current Workarounds
Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.
Get Solutions for This Problem
Full report with actionable solutions
- Solutions for this specific pain
- Solutions for all 15 industry pains
- Where to find first clients
- Pricing & launch costs
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Evidence Sources:
Related Business Risks
Betriebsprüfungsrisiken bei Lizenzierung
Hohe Bürokratiekosten in Klinikstudien-Verträgen
Verzögerte Marktzulassung durch regulatorische Hürden
Kosten durch Datenqualitätsmängel in Experimenten
Kapazitätsverluste durch manuelle Datenprotokollierung
DSGVO-Risiken bei sensiblen Biotechnologie-Daten
Request Deep Analysis
🇩🇪 Be first to access this market's intelligence